EGFR Tyrosine Kinase Mutation Testing in the Treatment of Non-Small-Cell Lung Cancer

Kamel‐Reid, Suzanne; Chong, George; Ionescu, Diana N.; Magliocco, Anthony M.; Spatz, Alan; Tsao, Ming‐Sound; Weng, Xiaoduan; Young, Sean; Zhang, T; Soulières, Denis

doi:10.3747/co.19.862

Cited by 16 publications

(12 citation statements)

References 31 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…24,25 The detection limit has been established at 1% to 5% by serial dilutions of relevant cell line DNA. 24,25 The detection limit has been established at 1% to 5% by serial dilutions of relevant cell line DNA.…”

Section: Egfr Mutation Testingmentioning

confidence: 99%

Sample Features Associated with Success Rates in Population-Based EGFR Mutation Testing

Shiau

Babwah

Santos

et al. 2014

Journal of Thoracic Oncology

104

View full text Add to dashboard Cite

show abstract

Section: Egfr Mutation Testingmentioning

confidence: 99%

Sample Features Associated with Success Rates in Population-Based EGFR Mutation Testing

Shiau

Babwah

Santos

et al. 2014

Journal of Thoracic Oncology

104

View full text Add to dashboard Cite

show abstract

“…Additionally, samples were tested for the L858R point mutation in exon 21 by pcr and restriction fragment length polymorphism analysis. Both pcr assays were controlled for a minimum detection threshold of 2% mutant dna 14, 15 .…”

Section: Methodsmentioning

confidence: 99%

Relationship of Thyroid Transcription Factor 1 to EGFR Status in Non-Small-Cell Lung Cancer

et al. 2014

Self Cite

View full text Add to dashboard Cite

Background: Activating mutations of the epidermal growth factor receptor (EGFR) gene are known to drive a proportion of non-small-cell lung cancers. Identification of lung cancers harbouring such mutations can lead to effective treatment using one of the agents that targets and blocks EGFR-mediated signalling. Methods: All specimens received at the BC Cancer Agency (Vancouver) for EGFR testing were prospectively identified and catalogued, together with clinical information and EGFR status, over a 14-month period. Results: Specimens from 586 patients were received for EGFR testing, and EGFR status was reported for 509 patients. No relationship between specimen type or site of origin and EGFR test failure rate was identified. Concurrent immunohistochemical (IHC) status for thyroid transcription factor 1 (TTF1) was available for 309 patients. The negative predictive value of TTF1-negative status by IHC was 94.2% for predicting negative EGFR status. Conclusions: In patients with limited tissue available for testing, a surrogate for EGFR status would aid in timely management. Immunohistochemistry for TTF1 is readily available and correlates highly with EGFR status. In conjunction with genetic assays, TTF1 could be used to optimize an EGFR testing strategy.

show abstract

“…Deletions in exon 19 of the EGFR gene constitute one type of such mutations. These deletions most commonly affect 9, 12, 15, 18 or 24 nucleotides [3]. Some of these deletions share a common feature -they cause the removal of four amino acids in codons 747-750: leucine, arginine, glutamic acid, and alanine.…”

Section: Genomicsmentioning

confidence: 99%

“…Some of these deletions share a common feature -they cause the removal of four amino acids in codons 747-750: leucine, arginine, glutamic acid, and alanine. The second most common mutation in the EGFR gene is substitution in exon 21, mainly L858R [3].…”

Section: Genomicsmentioning

confidence: 99%

EXPERIMENTAL CARDIOVASCULAR AND LUNG RESEARCH From mutation to methylation – molecular markers in lung cancer

Lewandowska¹,

Grębicka²,

Chrustek³

et al. 2013

kitp

View full text Add to dashboard Cite

StreszczenieRak płuca jest najczęstszym oraz najgorzej rokującym nowotworem złośliwym na świecie oraz w Polsce. Na świecie z jego powodu umiera ok. 2 mln osób rocznie, w Polsce odnotowuje się ok. 14,5 tys. zachorowań u mężczyzn, a u kobiet rak płuca zajmuje trzecie miejsce z ponad 6 tys. zachorowań. Przyczyną powstawania raka płuca u 85% mężczyzn i u 47% kobiet jest palenie papierosów. W ciągu ostatnich lat nastąpił ogromny postęp wysokozaawansowanych i wysokorozdzielczych technologii z zakresu biologii molekularnej, takich jak sekwencjonowanie nowej generacji, mikromacierze, spektrometria mas, co przyczyniło się do rozwoju badań z zakresu genomiki, transkryptomiki i epigenetyki w raku płuca. Coraz szybsze wdraża-nie wyników tych dyscyplin pozwala na wykorzystanie analiz somatycznych mutacji punktowych czy translokacji do molekularnej diagnostyki onkologicznej, a tym samym na personalizację leczenia pacjentów z niedrobnokomórkowym rakiem płuca. Niestety, nadal brakuje zarówno markerów predykcyjnych, jak i prognostycznych, które pomogłyby w wykrywaniu raka płuca we wczesnym etapie rozwoju choroby. Słowa kluczowe: markery molekularne, personalizowana onkologia, diagnostyka molekularna. Kardiochirurgia i Torakochirurgia Polska 2013; 10 (2) 148 EXPERIMENTAL CARDIOVASCULAR AND LUNG RESEARCH AbstractLung cancer is one of the most common types of malignant neoplasms in Poland and in the world, and is associated with the worst prognosis. Within recent years, significant progress has been made when it comes to high-throughput and highresolution technologies in the field of molecular biology, i.e. next-generation sequencing, microarrays, and mass spectrometry, which contributed to the development of research in the fields of genomics, transcriptomics and epigenetics in lung cancer. Implementing the results achieved by these disciplines quickly allows for the analysis of somatic point mutations or translocations to be used in molecular cancer diagnostics, and, thus, for the personalization of treatment for patients with non-small cell lung cancer (NSCLC). Unfortunately, certain markers and prognostic predictors that could facilitate the detection of lung cancer in its early stages are yet to be found.

show abstract

EGFR Tyrosine Kinase Mutation Testing in the Treatment of Non-Small-Cell Lung Cancer

Abstract: ConclusionsOur results suggest that currently available methods are capable of reliably detecting exon 19 and exon 21 mutations of EFGR in tumour samples (provided that sufficient tumour material is available) and that routine screening for those mutations is feasible in clinical practice.

Cited by 16 publications

References 31 publications

Sample Features Associated with Success Rates in Population-Based EGFR Mutation Testing

Sample Features Associated with Success Rates in Population-Based EGFR Mutation Testing

Relationship of Thyroid Transcription Factor 1 to EGFR Status in Non-Small-Cell Lung Cancer

EXPERIMENTAL CARDIOVASCULAR AND LUNG RESEARCH From mutation to methylation – molecular markers in lung cancer

Contact Info

Product

Resources

About